

Certificate of Analysis

VIAL REFERENCE

VT-4F2A9C17B3E8

LABORATORY REPORT

AR-26-01937 · v1.0

RECEIVED / ANALYSED / ISSUED

02 Oct 2026 · 06 Oct 2026 · 08 Oct 2026

01 / SAMPLE

Retatrutide

Lyophilised powder, single sealed vial. Label claim 10.00 mg/vial.

Sample reference

VT-S-26-0417

Batch as supplied

RT-260905

Condition on receipt

Sealed vial, cap intact, no visible damage; stored at 2–8 °C on receipt

Submitted by

Customer-submitted sample



SAMPLE AS RECEIVED

02 / RESULTS

IDENTITY / LC-MS

Match

Consistent with retatrutide

PURITY / HPLC-UV

99.7

 % area

Relative integrated peak area, 214 nm

CONTENT / QUANTITATIVE HPLC

10.08

 mg/vial

100.8 % of label claim · U = ±2.1 % (k = 2)

ASSESSMENT

Reported as found

All three measurements are reported with their methods on pages 2 and 3. No pass/fail specification was requested by the customer. Endotoxin, heavy metals and sterility were not part of this scope.

03 / ANALYSIS, REVIEW AND AUTHORISATION

ANALYSIS / TECHNICAL REVIEW

Name, qualifications and role

Signature / approval reference

Date

LABORATORY AUTHORISATION

Name, qualifications and role

Signature / approval reference

Date

Check this report


Scan the code or go to vialtesting.com.au/verify and enter the Vial reference above. The verification key, supplied separately, shows the full registered record and lets you compare this PDF with the registered file.



Purity by HPLC-UV

04 / METHOD

HPLC-UV, 214 nm, C18 2.1 × 100 mm, 1.7 µm, water/acetonitrile with 0.1 % TFA, 5 µL injection. Sample prepared by reconstituting one whole vial to 10.00 mL in diluent; peak areas integrated between 1.0 and 12.0 min; peaks below 0.05 % area not reported.



PEAK	RETENTION (MIN)	AREA (%)
Minor peak	2.84	0.12
Retatrutide (principal peak)	6.41	99.70
Minor peak	7.95	0.11
Minor peak	9.30	0.07

Area % = peak area ÷ sum of all integrated peak areas × 100. Response factors not applied.


05 / REPORTING BASIS

Chromatographic purity is a proportion of the detector response, reported on an area-normalised basis. It is not the mass fraction of the powder in the vial: salts, counter-ions, water and non-UV-absorbing material are not measured by this method. Co-eluting species would not be resolved as separate peaks. The integrated trace and instrument data file are retained by the laboratory and available on request.

Identity and content

06 / IDENTITY BY LC-MS

LC-ESI-MS, positive ion, charge-state deconvolution. The sample spectrum was compared with the expected mass of retatrutide across four charge states.



CHARGE STATE	EXPECTED M/Z	OBSERVED M/Z
[M + 3H]3+	1578.44	1578.49
[M + 4H]4+	1183.83	1183.86
[M + 5H]5+	947.27	947.29
[M + 6H]6+	789.56	789.58


Deconvoluted average mass 4731.5 Da

Expected 4731.3 Da · difference 0.2 Da

Interpretation: the observed charge-state series and deconvoluted mass are consistent with retatrutide within the method tolerance of ± 0.5 Da. Mass agreement does not distinguish all possible isomers and does not establish sequence; identity is reported as consistent with the stated compound.

07 / CONTENT BY QUANTITATIVE HPLC

Quantitative HPLC-UV against a qualified reference standard, external calibration. Six calibration standards from 0.2 to 1.2 mg/mL; sample reconstituted to 10.00 mL; result expressed per vial.



CALCULATION

Calibration: response = 1000 × c + 12 (r² = 0.9998)

1020 a.u. gives 1.008 mg/mL

1.008 mg/mL × 10.00 mL × 1

= 10.08 mg/vial

10.08 / 10.00 × 100 = 100.8 % of label claim

Expanded uncertainty ± 2.1 % (k = 2). Standards traceable to the laboratory's qualified reference material; QC check standard within acceptance.